Seeking Alpha

Atlantic Equities upgrades Bristol-Myers Squbb (BMY) to "Neutral" from "Underweight" and sets a...

Atlantic Equities upgrades Bristol-Myers Squbb (BMY) to "Neutral" from "Underweight" and sets a price target of $32.50 after the FDA approved the company's Eliquis anti-clotting drug last week. BMY is +2% at $32.55 premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)